ライフサイエンスコーパス: ravuconazole

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 redict the susceptibility of Candida spp. to ravuconazole.

2 fluconazole, voriconazole, posaconazole, and ravuconazole.

3 redict the susceptibility of Candida spp. to ravuconazole.

4 ew triazoles voriconazole, posaconazole, and ravuconazole.

5 of isolates at <or=1 microg/ml, followed by ravuconazole (91%), voriconazole (90%), and itraconazole

6 A current example is ravuconazole, a new triazole antifungal with an expanded

7 gin, a new echinocandin, in combination with ravuconazole, a second-generation triazole, against expe

8 Voriconazole, posaconazole, and ravuconazole all were very active (99% of isolates susce

9 edative dexmedetomidine, and two antifungals ravuconazole and posaconazole.

10 of cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate m

11 Of the antifungal agents tested, ravuconazole and voriconazole displayed the greatest spe

12 Both ravuconazole and voriconazole were significantly more ac

13 Ravuconazole and voriconazole were the most active agent

14 w triazoles (voriconazole, posaconazole, and ravuconazole), and amphotericin B.

15 amphotericin B, itraconazole, voriconazole, ravuconazole, and posaconazole.

16 The investigational triazoles posaconazole, ravuconazole, and voriconazole had excellent in vitro ac

17 ment was good to excellent for itraconazole, ravuconazole, and voriconazole MFCs with RPMI and M3 (93

18 The investigational triazoles posaconazole, ravuconazole, and voriconazole were all highly active ag

19 ) MICs of three new triazoles (posaconazole, ravuconazole, and voriconazole) and the echinocandin cas

20 d variable cross-resistance to posaconazole, ravuconazole, and voriconazole.

21 ne, fluconazole, itraconazole, posaconazole, ravuconazole, and voriconazole.

22 Cross-resistance between fluconazole and ravuconazole applies most directly to fluconazole-resist

23 azoles all have some in vitro activity, with ravuconazole being the most active (MIC(50), 0.25 microg

24 ecies were inhibited by < or =1 microg/ml of ravuconazole (concentration at which 50% were inhibited

25 hagas, and antifungal drugs posaconazole and ravuconazole have entered clinical trials in Spain, Boli

26 agonism between liposomal amphotericin B and ravuconazole in simultaneous treatment of experimental i

27 Since ravuconazole is 16- to 32-fold more potent than fluconaz

28 of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole, and amphotericin B against 4

29 Ravuconazole MICs and tentative interpretive categories

30 with itraconazole (ITR), posaconazole (POS), ravuconazole (RAV), and voriconazole (VOR).

31 voriconazole (VOR), posaconazole (POS), and ravuconazole (RAV).

32 azole MICs of </=32 microg/ml susceptible to ravuconazole, resulting in a categorical agreement rate

33 nce of fluconazole as a surrogate marker for ravuconazole susceptibility was improved by designating

34 or each antifungal agent ranged from 96% for ravuconazole to 100% for amphotericin B.

35 laboratories of itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B MFCs for

36 n B, flucytosine, fluconazole, posaconazole, ravuconazole, voriconazole, and caspofungin of 601 invas

37 Ravuconazole, voriconazole, and fluconazole were highly

38 rains were inhibited by < or =1 microg/ml of ravuconazole, voriconazole, itraconazole, and amphoteric

39 Ravuconazole was active (MIC, </=1 microg/ml) against 99

40 fluconazole, voriconazole, posaconazole, and ravuconazole were determined by the National Committee f

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。